The Patent Finder

Qu Biologics Inc.

Also on record
Records under this name other than the patents Qu Biologics Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 5 patents it holds.

Showing 1 to 9 of 9 · Back to Qu Biologics Inc.

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 9,320,788Tissue targeted antigenic activation of the immune response to treat cancers
Term ended
Term ended Feb 15, 2026 · USPTO record
Term endedTerm ended Feb 15, 2026USPTO record
US 11,226,340Therapeutically triggering an innate immune response in a target tissue
Lapsed on the fee record
Ended Jan 18, 2026 · USPTO record
Lapsed on the fee recordEnded Jan 18, 2026USPTO record
US 9,320,787Tissue targeted antigenic activation of the immune response to treat cancers
Term ended
Term ended Jan 17, 2026 · USPTO record
Term endedTerm ended Jan 17, 2026USPTO record
US 8,034,359Tissue Targeted Antigenic Activation of the Immune Response to Cancers
Term ended
Term ended Dec 14, 2025 · High confidence
Term endedTerm ended Dec 14, 2025High confidence
US 10,130,692Immunogenic anti-inflammatory compositions
Term ended
Term ended Oct 8, 2025 · USPTO record
Term endedTerm ended Oct 8, 2025USPTO record
US 8,501,198Tissue Targeted Antigenic Activation of the Immune Response to Treat Cancers
Lapsed on the fee record
Ended Aug 6, 2025 · Medium confidence
Lapsed on the fee recordEnded Aug 6, 2025Medium confidence
US 9,107,864Tissue Targeted Antigenic Activation of the Immune Response to Treat Cancers
Term ended
Term ended May 30, 2025 · High confidence
Term endedTerm ended May 30, 2025High confidence
US 9,775,896Tissue Targeted Antigenic Activation of the Immune Response to Treat Cancers
Term ended
Term ended May 30, 2025 · High confidence
Term endedTerm ended May 30, 2025High confidence
US 10,086,066Tissue Targeted Antigenic Activation of the Immune Response to Treat Cancers
Term ended
Term ended May 30, 2025 · High confidence
Term endedTerm ended May 30, 2025High confidence
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited